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Valproic acidDBA/2J mice, which have homozygous mutations in Cdh23 and Fscn2, are characterized by early onset hear-
ing loss at as early as three-weeks of age (Noben-Trauth et al., 2003 [1]) and are an animal model for pro-
gressive hearing loss research. Recently, it has been reported that epigenetic regulatory pathways likely
play an important role in hearing loss (Provenzano and Domann, 2007 [2]; Mutai et al., 2009 [3]; Waldhaus
et al., 2012 [4]). We previously reported that DBA/2J mice injected subcutaneously with a combination of
epigenetic modifying reagents, L-methionine (MET) as methyl donor and valproic acid (VPA) as a pan-
histone deacetylases (Hdac) inhibitor, showed a signiﬁcant attenuation of progressive hearing loss by mea-
suring their auditory brainstem response (ABR) thresholds (Mutai et al., 2015 [5]). Here we present genome
wide expression proﬁling of the DBA/2J mice cochleae, with and without treatment of MET and VPA, to
identify the genes involved in the reduction of progressive hearing loss. The raw and normalized data
were deposited in NCBI's Gene Expression Omnibus (GEO ID: GSE62173) for ease of reproducibility and
reanalysis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcationsrganism/cell
line/tissueMus musculus (DBA/2J)x Male
quencer or
array typeAffymetrix GeneChip Mouse Genome 430 2.0 Arrayata format Raw data: CEL ﬁles, normalized data: SOFT, MINiML and TXT
ﬁlesxperimental
factorsDBA/2J mice at 4 weeks of age (untreated), 12 week old mice
treated with control vehicle
(0.1 M sodium bicarbonate) for 8 weeks, and 12 week old
mice
treated with L-methionine and valproic acid were analyzed.xperimental
featuresMicroarray gene expression proﬁling to identify transcripts
that are regulated by L-methionine
and valproic acid in cochleae of
DBA/2J mice as an animal model for hearing lossonsent Not applicable
mple source
locationMice were purchased from Clea Japan (Tokyo, Japan).nce Mathematics, RIKEN Center
, Yokohama, Japan.
a).
. This is an open access article under1. Direct link to deposited data
The deposited data can be found at: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE62173.2. Experimental design, materials and methods
DBA/2J mice, which have homozygous mutations in Cdh23 and
Fscn2, are characterized by early onset hearing loss as early as
three-weeks of age [1] and are an animal model for progressive hear-
ing loss research. Recently, it has been reported that epigenetic reg-
ulatory pathways likely play an important role in hearing loss [2–4].
We previously reported that DBA/2J mice injected subcutaneously
with a combination of epigenetic modifying reagents, l-methionine
(MET) as a methyl donor and valproic acid (VPA) as a pan-histone
deacetylase (Hdac) inhibitor, showed a signiﬁcant attenuation of
progressive hearing loss by measuring their auditory brainstem re-
sponse (ABR) thresholds [5]. Here we investigated genome wide ex-
pression proﬁling of the DBA/2J mice cochleae, with and without
treatment of MET and VPA, to identify the genes involved in the re-
duction of progressive hearing loss.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1.Workﬂow of the experiments and analyses.
Fig. 2. Scatter plot of the microarray data. Mean expression signals of the vehicle-treated
controlmice of 12weeks of age againstmean expression signals of theMET+VPA-treated
mice of 12 weeks of age. The signal values were transformed to a logarithmic scale (base
2). The cyan line shows y = x (no difference), the cyan dotted-lines show a 1.5-hold
change. The black and red dots represent non-differentially and differentially expressed
probes (p-value b 0.05 and fold change ≥ 1.5), respectively.
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DBA/2J mice were purchased from Clea Japan (Tokyo, Japan). Mice
were housed in plastic cages with metallic lid in a room with a 12-h
light/dark cycle and 55% humidity at 23 °C and had free access to food
and water. Male DBA/2J mice at 4-weeks postnatal age were used as
non-treatment young controls (Fig. 1). In vitro treatment mice with
epigenetic modifying reagents were male DBA/2J mice of 4-weeks of
age subcutaneously injected once daily for 8 weeks with L-methionine
(MET; 500mg/kg/day,WakoPureChemicals, Osaka, Japan) and valproic
acid (VPA; 300 mg/kg/day, Sigma-Aldrich, MO, USA) in 0.1 M sodium
bicarbonate (10 ml/kg body weight) (MET + VPA, Fig. 1). The age-
matched control mice were male DBA/2J mice of 4-weeks old subcuta-
neously injected once daily for 8weekswith only vehicle (0.1M sodium
bicarbonate) (Fig. 1). The hearing loss phenotype was investigated by
measurement of auditory brainstem response (ABR) as previously re-
ported [5]. A signiﬁcant attenuation effect of progressive hearing loss
was observed and validated in mice injected with MET and VPA as pre-
viously reported [5]. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of National TokyoMedical
Center (permit number: 12-animal-02). The experiments were carried
out in accordance with the approved guidelines.
2.2. Microarray experiments
Total RNA was extracted from the whole left cochleae of mice using
TRIzol reagent (Life Technologies, CA, USA) and further puriﬁed using
the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer's instruction. The quality of the RNA was assessed using
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). We used
only the high quality RNA (RIN score N7), derived from 5 to 6 mice in
each group, for microarray experiments (Fig. 1). For microarray hybrid-
ization, the biotinylated aRNA was prepared according to the standard
Affymetrix protocol using GeneChip 3′ IVT Express Kit (Affymetrix, CA,
USA) from the 250 ng total RNA. Then, 10 μg of aRNA was hybridized
for 16 h at 45 °C on GeneChip Mouse Genome 430 2.0 Array
(Affymetrix) with 45,101 probes. The GeneChips were washed and
stained in the Affymetrix Fluidics Station 450. The stained GeneChips
were scanned using the Affymetrix Scanner 3000 7G, the images were
digitalized using GeneChip Operating Software (GCOS) v.1.3
(Affymetrix), and the data were exported as CEL ﬁles.
2.3. Data normalization
Gene expression array data were normalized using the MAS5
algorithm (Affymetrix). The intensities were converted to a logarithmic
scale (base 2). To correct for bias between chips, we then performedquantile normalization [6] to all array data using R software (“affy”
and “limma” packages). The signal reliability of each probe was
determined based on the MAS5 Call algorithm (Affymetrix), and each
probe was assigned to one of three ﬂags (P: present, M: marginal, and
A: absent).
2.4. Validation of microarray data by qRT-PCR
Among the genes that were highly differentially expressed between
theMET+VPA and vehicle control group inmicroarray data, we select-
ed 8 genes (Otx1, Slc39a4 (also known as Zip4), Calca, Pold3, Hspa1b,
Serpinh1, Gabra1 and Gabra2) to validate the expression levels by qRT-
PCR [5]. For the qRT-PCR, the total RNA was reverse transcribed using
SuperScript III (Life Technologies, CA, USA) with random hexamer
d(N)6 primers. The details were described in our previous report [5].
2.5. Differentially expressed genes and cluster analysis
To identify possible genes involved in attenuation of progressive
hearing loss induced by MET and VPA, we compared the cochleae ex-
pression of MET + VPA to the vehicle control group using Welch's
Fig. 3.Cluster and statistical analysis results for the top 20 differentially up- or down-regulated genes in theMET+VPA-treated cochleae relative to vehicle-treated control cochleae of 12-
week old mice. The cluster analysis was performed using 16 samples (4-weeks non-treated control mice, N= 5; 12-weeks vehicle-treated mice, N= 5; 12-weeks MET + VPA-treated
mice, N= 6). *GenBank IDs start with “B”.
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(P) ﬂag for all samples in at least one group for the statistical tests,
24,787 probes remained. Genes were considered differentially
expressed with a p-value b 0.05 and a fold change ≥ 1.5.Using these
criteria, 55 probes (49 genes) and 244 probes (195 genes) were up-
and down-regulated in the MET + VPA group, respectively (Fig. 2).
Cluster analysis was performed using the average linkage method
with Euclidian distance in Cluster and TreeView [7] (Fig. 3).
3. Discussion
We present a dataset of microarray expression proﬁling of the DBA/
2J mice cochleae treated with and without an epigenetic modifying re-
agent to investigate the genes involved in the reduction of progressive
hearing loss. In our previous report [5], we particularly focused on
Slc39a4 (also known as zinc importer Zip4) from the microarray data.
In addition to Scl39a4, other genes differentially expressed in the pres-
ence of theMET andVPAmay contribute to the observed attenuation ef-
fect on progressive hearing loss. We believe that this expression
proﬁling dataset would be valuable for further investigating and under-
standing of the molecular mechanism in hearing loss.
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